| 摘要: |
| BCL-2是调节细胞凋亡的关键蛋白,在很多血液系统恶性肿瘤中高表达,发挥抗凋亡作用。维奈克拉是首个高度选择性的BCL-2抑制剂,在全球范围内其第一个适应证为慢性淋巴细胞白血病(CLL),目前临床研究更已拓展到多种B细胞淋巴瘤、骨髓增生异常综合征(MDS)等多个血液肿瘤。本文对维奈克拉在B细胞淋巴瘤中的治疗进展作一综述。 |
| 关键词: 维奈克拉 B细胞淋巴瘤 B细胞淋巴瘤因子-2 治疗 进展 |
| DOI:10.13506/j.cnki.jpr.2023.06.011 |
| 基金项目: |
|
|
|
| Progress in the treatment of Bcl-2 inhibitor Venetoclax in B-cell lymphoma |
| PAN Yu,CHEN Weiwei,LIU Nan |
| (Department of Hematology, Heze Municipal Hospital in Shandong Province, Heze 274000, China) |
| Abstract: |
| Bcl-2 protein is a key protein in regulating cell apoptosis, which is highly expressed in many hematological malignancies and plays an anti-apoptotic role. Venetoclax is the first highly selective bcl-2 inhibitor. Its first indication in the world is chronic lymphocytic leukemia (CLL), and clinical studies have been extended to a variety of B-cell lymphoma, myelodysplastic syndrome (MDS) and other hematological tumors. This review reviewed the therapeutic progress of venetoclax in B-cell lymphoma. |
| Key words: Venetoclax B-cell lymphoma Treatment Progress |